Integrated psychedelic drug development and wellness company focusing on therapeutic uses of psychedelics to address mental illnesses NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) has submitted a new patent application for its novel mechanism of weight loss targeted to specific fat substances.
NoenMind filed the provisional patent application with the Unites States Patent and Trademark Office (USPTO). The patent includes data extracted from the company’s recent preclinical animal study incorporating novel findings which showed that in addition to reiterating weight modulation effects of psilocybin seen in previous studies.
The studies proved that targeted reduction of specific fat substances may have beneficial effects on metabolic and cardiovascular health.
“We are excited by the unique findings from our preclinical studies, which have demonstrated durable therapeutic benefits for weight management in the animal model. Importantly, our novel findings provide an opportunity for us to develop drugs with highly differentiated target product profiles and broad commercial opportunities,” said the company’s CEO, Robert Tessarolo.
When granted the patent for the company’s lead candidate, NEO-001 aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity.
Tessarolo claims NoenMind’s additional candidate NEO-002 employs low-dose psilocybin to control appetite.
“With the advancement of our research programs and continued expansion of our IP portfolio, NeonMind is positioning itself as a leading innovator in the development of novel psychedelic treatments focused on serving the weight management and obesity market, which has historically been underserved and where a new, effective approach is desperately needed to help people live fuller, healthier lives,” added the CEO.